Shareholder Value and Financial Outlook
RECENT ANNOUNCEMENTS
| ↑ ↑ ↑
CENTENE CONTRACT
5 year pharmacy benefit services
contract starting 1/1/24 driving value
and lower costs for ~20M Centene
members
Implementation headwind in 2023,
neutral to slightly positive in 2024,
run-rate margin in 2025+
Financially accretive
over the contract period
7/7
BIOSIMILARS
Driving lower costs by adding
Humira biosimilars to National
Preferred Formulary
Humira will remain as co-preferred
providing choice and flexibility
Other biosimilars will be
evaluated as they come to market
VillageMD AND SUMMIT
Up to $2.7B equity
investment for ~14% stake
in combined company
Attractive 5.5% annual
dividend on
$2.2B of $2.7B investment
Innovative partnership
accelerating our value
based care strategy
Confidential, unpublished property of Cigna. 2023 CignaView entire presentation